Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations Between Opioid Timing and Postoperative Desaturation Burden Following Metabolic Bariatric Surgery.

Obesity surgery·2026
Same author

Lessons from biotech's unscientific evolution.

Nature biotechnology·2026
Same author

Investigating the correlation between force output, strains, and pressure for active skeletal muscle contractions.

Journal of the mechanical behavior of biomedical materials·2026
Same author

Few-Shot Transfer Learning for Diabetes Risk Prediction Across Global Populations.

Medicina (Kaunas, Lithuania)·2026
Same author

Point-of-Care Tongue Ultrasound for Perioperative Risk Stratification in Metabolic Bariatric Surgery.

Obesity surgery·2025
Same author

Phenylephrine Usage During Anesthesia in Concussed Patients Undergoing Orthopedic Surgery: A Retrospective Cohort Study.

Cureus·2025

Related Experiment Video

Updated: Nov 5, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.3K

Private biotech 2004--the numbers.

John Hodgson1

  • 1Critical I Limited, The Colin Sanders Innovation Centre, Mewburn Road, Banbury, OX16 9PA, UK. john.hodgson@criticali.net

Nature Biotechnology
|June 10, 2006
PubMed
Summary
This summary is machine-generated.

Financial insights into private biotechnology firms are scarce. This analysis examines the financial performance of the privately held biotech sector, offering a rare glimpse into this often-overlooked industry.

More Related Videos

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

2.7K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.7K

Related Experiment Videos

Last Updated: Nov 5, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.3K
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

2.7K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.7K

Area of Science:

  • Biotechnology
  • Biopharmaceutical industry
  • Health economics

Background:

  • Publicly traded biotechnology companies receive significant financial coverage.
  • Limited financial data is available for private biotechnology firms.
  • Understanding the private biotech sector is crucial for a comprehensive view of the industry.

Purpose of the Study:

  • To analyze the financial performance of the privately held biotechnology sector.
  • To provide insights into the economic landscape of private biotech companies.
  • To bridge the knowledge gap regarding the financial health of non-public biotech entities.

Main Methods:

  • Analysis of financial data from privately held biotech firms.
  • Comparative financial performance assessment.
  • Industry-wide financial review of the private biotech sector.

Main Results:

  • Detailed financial performance metrics for private biotech firms.
  • Identification of key financial trends within the sector.
  • Benchmarking of financial health across private biotechnology companies.

Conclusions:

  • The private biotech sector exhibits distinct financial characteristics.
  • This analysis provides valuable financial intelligence for stakeholders in the biotechnology industry.
  • Further research into private biotech firm finances is warranted.